Acne News and Research

Latest Acne News and Research

Stoptober campaign focuses on skin disease research

Stoptober is a UK-wide campaign to get the nation to quit smoking. We, the British Skin Foundation, are asking that Stoptober participants get a friends, family & colleagues to sponsor your efforts and raise some money for skin disease research at the same time.

22 Sep 2015

Researchers report significant progress in management of patients with dry eyes

Do you have problems with dry eyes? If so, you're not alone--it's one of the most common reasons for patient visits to eye care professionals. Recent years have seen significant progress in management of patients with dry eyes, according to the September special issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

28 Aug 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

New TSRI discovery could open way to incorporate sulfur into natural antibiotic products

In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.

11 Aug 2015

Syneron Medical's second quarter 2015 revenue up 14% to $73.5 million

Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2015.

4 Aug 2015

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.

16 Jul 2015

Cassiopea selects DATATRAK platform for significant global study

DATATRAK International, Inc., the leader in developing cloud-based, unified dClinical technologies and delivering related services for the clinical trials industry, today announced that Cassiopea S.p.A., the newly IPO'd former subsidiary of longtime partner Cosmo Pharmaceuticals SA has selected DATATRAK for a significant global study.

15 Jul 2015

LUX-Lung 8 supports afatinib in squamous NSCLC

Compared with erlotinib, treatment with afatinib leads to outcomes in previously treated patients with advanced squamous non-small-cell lung cancer, suggest the results of a head-to-head trial.

8 Jul 2015

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

2 Jul 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

Zapne offers better alternative to available acne treatments

After a decade of research, Zapne LLC has released its signature acne treatment, Zapne, an all-natural product to treat acne without the harsh side effects of many current regimens. Zapne offers four key advantages over most acne treatments: The treatment system is formulated from natural, non-synthetic ingredients, produces no material side effects, requires only a single 15-minute weekly application, and produces visible results quickly, in some cases after only one or a few applications.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found.

15 May 2015

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher Pharmaceuticals Inc. today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company. Both products have been approved by Health Canada.

6 May 2015

New web-based platform launched to provide acne care to patients across Pennsylvania

Dr. Jamie Altman, owner and president of Aesthetic Dermatology Associates, PC, a dermatology practice based in the Philadelphia suburbs of Media and Paoli, today announced the launch of AcneCareMD.com, a secure telemedicine website designed to provide acne care to patients across Pennsylvania via a web-based platform.

31 Mar 2015

New targeted therapy promises to reduce frequency and intensity of breakouts

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Acne News and Research

Latest Acne News and Research

Stoptober campaign focuses on skin disease research

Researchers report significant progress in management of patients with dry eyes

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

New TSRI discovery could open way to incorporate sulfur into natural antibiotic products

Syneron Medical's second quarter 2015 revenue up 14% to $73.5 million

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

Cassiopea selects DATATRAK platform for significant global study

LUX-Lung 8 supports afatinib in squamous NSCLC

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Zapne offers better alternative to available acne treatments

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

New web-based platform launched to provide acne care to patients across Pennsylvania

New targeted therapy promises to reduce frequency and intensity of breakouts

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Acne News and Research

Latest Acne News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in